Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atamparib - Ribon Therapeutics

Next Previous
X
Search
Drug Profile

Atamparib - Ribon Therapeutics

Alternative Names: ONO-7119; RBN-2397

Latest Information Update: 27 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ribon Therapeutics
  • Developer Ono Pharmaceutical; Ribon Therapeutics
  • Class Amines; Antineoplastics; Ethers; Fluorinated hydrocarbons; Ketones; Piperazines; Pyridazines; Pyrimidines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 7 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Squamous cell cancer
  • Phase I Solid tumours

Most Recent Events

  • 27 Apr 2023 3776005 - updated intro, KDM, added DEV lines, added TT data, minor updates in AE and PD data, added HE
  • 14 Apr 2023 Efficacy and adverse events data from a phase I/II trial in Squamous cell cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 14 Apr 2023 Pharmacodynamics data from a preclinical trial in solid-tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top